ALNA Allena Pharmaceuticals Inc.

2.5
+0.31  (+14%)
Previous Close 2.19
Open 2.23
Price To Book 2.34
Market Cap 58,664,163
Shares 23,465,665
Volume 353,382
Short Ratio
Av. Daily Volume 347,784
Stock charts supplied by TradingView

NewsSee all news

  1. Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities

    – Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) – – Plan to Re-Engage with U.S. Food and Drug Administration (FDA) to Evaluate Opportunities to Streamline URIROX-2, Second Pivotal

  2. Allena Pharmaceuticals to Present at Evercore ISI 2nd Annual HEALTHCONx Conference

    NEWTON, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics

  3. Allena Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

     -- Reported Positive Topline Results from Pivotal Phase 3 URIROX-1 Trial of Reloxaliase in Enteric Hyperoxaluria (EH), with Statistically Significant Reduction in Urinary Oxalate (UOx) Compared to Placebo -- --

  4. Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results from URIROX-1 Trial and from Study 206

    Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria Phase 2 Study 206 Trial Demonstrates Substantial Plasma Oxalate

  5. Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria

    NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met primary endpoint, key secondary endpoint missed - November 7, 2019.
Reloxaliase ALLN-177 (URIROX-1)
Enteric Hyperoxaluria
Phase 2 presentation at ASN November 8, 2019.
Reloxaliase ALLN-177 (Study 206)
Primary hyperoxaluria
Phase 3 data due 2H 2021. Noted December 4, 2019 that it intends to discuss with the FDA a proposal to reduce target enrolment and conduct an earlier interim analysis.
Reloxaliase ALLN-177 (URIROX-2)
Enteric Hyperoxaluria

Latest News

  1. Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities

    – Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) – – Plan to Re-Engage with U.S. Food and Drug Administration (FDA) to Evaluate Opportunities to Streamline URIROX-2, Second Pivotal

  2. Allena Pharmaceuticals to Present at Evercore ISI 2nd Annual HEALTHCONx Conference

    NEWTON, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics

  3. Allena Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

     -- Reported Positive Topline Results from Pivotal Phase 3 URIROX-1 Trial of Reloxaliase in Enteric Hyperoxaluria (EH), with Statistically Significant Reduction in Urinary Oxalate (UOx) Compared to Placebo -- --

  4. Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results from URIROX-1 Trial and from Study 206

    Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria Phase 2 Study 206 Trial Demonstrates Substantial Plasma Oxalate

  5. Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria

    NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics

  6. Allena Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Enteric Hyperoxaluria and Potential for Reloxaliase

    NEWTON, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics

  7. Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September

    NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics